New Delhi: New cases of corona in India break new records every day. At the same time, India moves faster than other countries in the world in the event of death. In the meantime, there has been good news about the Desi Corona vaccine. The native corona vaccine developed by Bharat Biotech is the first phase of clinical trials with ‘Kovacine’. Now the Medicines Agency has also approved its second phase of the study.
The Subject Expert Committee has said that 380 people should be tried this time. The second phase of the Covaxin (Covaxin) human trials can begin in the coming weeks with the approval of the ethics committee. On September 3, the Joint Drugs Controller, Dr. S. Eshwara Reddy, in a letter to Hyderabad-based Bharat Biotech, that an Expert Committee has asked the company to start the second phase of the study. In the second phase of the study, this vaccine will be tested on 380 people.
Speaking of Covaxin: 375 volunteers from 12 cities across the country took part in the first phase of the study. Covicin is the dominant active ingredient in the domestic corona vaccine. Once the second phase of the cocaine trial begins, she will join the vaccines from Zydus Cadila and the Serum Institute of India, which are already undergoing phase two trials.
Also read, asthma patients have problems with the changing seasons, this Ayurvedic tea will bring relief
How Covaxin works
Let us know that cocaine is an inactivated vaccine that involves injecting a virus into the human body. Because of the non-pathogenic virus, a person will not get sick with this virus, but their body will make antibodies to fight this virus, so by the time the real virus attacks, the human body will be ready. Every step of the vaccine study is very important.
In the first phase of the vaccine, the health of the volunteers is monitored and it is determined that the vaccine dose is not causing any problems for the volunteers. After that, in the second phase of the experiment, it will be seen how effective this vaccine is for the virus and whether or not it can produce antibodies. In the third and final phase of studies, the company is seeing how effective this vaccine will be as a dose for a large population.
Click here to read more health news